Why the study?
Does DOAC use compared to warfarin reduce stroke/systemic embolism or major bleeding in real-world patients with atrial fibrillation?
Does DOAC use compared to warfarin reduce stroke/systemic embolism or major bleeding in real-world patients with atrial fibrillation?
In a real-world Japanese cohort of AF patients, DOACs showed comparable efficacy and safety to warfarin for stroke prevention and major bleeding.
No takes yet. Share an insight, caveat, or question.
Real-world AF patients show similar stroke and bleeding rates with DOACs versus warfarin; leaves open need for randomized confirmation before shifting practice.
Yamashita et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: